The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase II trial investigating whether atezolizumab after chemoradiotherapy (CRT) prolongs survival in limited stage (LS) small cell lung cancer (SCLC).
 
Bjorn Gronberg
Employment - Lilly (I)
Stock and Other Ownership Interests - Lilly (I)
Honoraria - AstraZeneca; BMS Norway; Gilead Sciences; Janssen; Lilly; MSD; Pfizer
Consulting or Advisory Role - Accord Healthcare; AstraZeneca; Janssen; MSD
Research Funding - AstraZeneca (Inst); Roche (Inst)
 
Marianne Aanerud
Honoraria - AstraZeneca; BMS Norway
 
Daphne Dumoulin
Consulting or Advisory Role - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squib; Bristol-Myers Squibb (Inst); MSD (Inst); Roche (Inst)
 
Jan Nyman
No Relationships to Disclose
 
Tine Schytte
No Relationships to Disclose
 
Maria Bjaanæs
No Relationships to Disclose
 
Kirill Neumann
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; MSD
 
Georgios Tsakonas
Honoraria - Roche; Roche
Consulting or Advisory Role - Accord Healthcare; Atheneum; MSD Oncology; Roche
Research Funding - MSD Oncology
 
Elisabeth Anna Kastelijn
No Relationships to Disclose
 
Nina Helbekkmo
No Relationships to Disclose
 
Seppo Langer
Employment - Novo Nordisk (I)
 
Sacha Rothschild
Honoraria - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Otsuka (Inst); Pfizer (Inst); PharmaMar (Inst); Roche Pharma AG (Inst); Sanofi (Inst); Takeda (Inst)
Consulting or Advisory Role - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Otsuka (Inst); Pfizer (Inst); PharmaMar (Inst); Roche Pharma AG (Inst); Takeda (Inst)
Speakers' Bureau - Amgen (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Roche Pharma AG (Inst); Sanofi/Aventis (Inst); Takeda (Inst)
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Merck Serono (Inst); Roche Pharma AG (Inst)
Travel, Accommodations, Expenses - Amgen (Inst); Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Roche Pharma AG (Inst); Sanofi; Takeda (Inst)
Other Relationship - Federal Drug Commission of the Swiss Federal Office of Public Health; Swiss Group for Clinical Cancer Research (SAKK) (Inst)
 
Christina Appenzeller
No Relationships to Disclose
 
Jos Stigt
No Relationships to Disclose
 
Tine McCulloch
No Relationships to Disclose
 
Hanne Sorger
Honoraria - AstraZeneca
Patents, Royalties, Other Intellectual Property - NLC Health, patent pending
 
Marie Søfteland Sandvei
No Relationships to Disclose
 
Kristin Killingberg
No Relationships to Disclose
 
Trude Camilla Frøseth
No Relationships to Disclose
 
Tarje Halvorsen
Honoraria - AstraZeneca; AstraZeneca; Pfizer; Takeda
Consulting or Advisory Role - AstraZeneca; Immedica; Immedica; Sanofi; Sanofi
Research Funding - AstraZeneca (Inst); MSD (Inst); Roche (Inst)